Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Clinical trial NCT02827877 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02827877
Sponsor: City of Hope Medical Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2 Positive Breast Carcinoma Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer

Start date: 2016-07-15
Primary completion: 2020-07-02
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.